The acquisition enables GE Healthcare to provide expanded end-to-end ecosystem of products solutions and services for its customers.

Cellular therapies are said to provide potentially curative treatments for several challenging diseases, including cancer.

Based in Lake Geneva region, Biosafe is engaged in the design, manufacture and marketing of automated cell processing systems.

The firm’s solutions can be used in bioprocessing, regenerative medicine and stem cell banking applications.

With operations in around 50 countries, the company operates through regional subsidiaries situated in Geneva of Switzerland, Hong-Kong and Shanghai of China, as well as São Paulo of Brazil.

The acquisition is part of GE’s strategy to develop a digitally-enabled ecosystem of complete tools, solutions and services for cell therapy.

GE Healthcare life sciences CEO Kieran Murphy said: “GE is building a world-class set of tools, technologies and services for cell and gene therapy and Biosafe’s expertise and innovative systems will strongly enhance our customer offering.

Biosafe Group founder and chairman Claude Fell said: “Together with GE we will have the combination of biological, engineering and industrial capabilities to help accelerate the fields of cell therapy and cellular immunotherapy into the mainstream, benefitting patients globally, and bringing the vision of personalized medicine to reality.”

In April, GE Ventures and Mayo Clinic launched Vitruvian Networks, an independent platform company that will offer access to cell and gene therapies through cloud-ready software systems and manufacturing services.

Earlier this year, NeoGenomics acquired GE Healthcare's Life Sciences business unit Clarient and its wholly-owned subsidiary Clarient Diagnostic Services, for around $275m.

Image: GE Healthcare has acquired Switzerland-based Biosafe Group. Photo: courtesy of stockimages /